Tanaz Ferzandi
Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CANPI 1952382756
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,119 of the $60,251 with a category attached, or 79.9%. 13 manufacturers reported payments, led by Cytyc Surgical Products, LLC at 37.8% of the total. Reporting peaked in 2023 at $25,757 and has fallen 94.7% since, to $1,355 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $459.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cytyc Surgical Products, LLC$23K
- Hologic Sales And Service, LLC$15K
- Coloplast$14K
- Intuitive Surgical$4K
- Boston Scientific$2K
- Medtronic$925
- plus $1K from 7 others
Across 14 payments — averaging $20,255 each. An ownership or investment interest held by the physician or an immediate family member.
- Phasor Health, LLC$234K
- Smarter Devices, LLC$50K
What the payments were for
- Consulting fees$48,11980%
- Grants$270%
- Travel & lodging$4,1057%
- Food & beverage$7,32312%
- Education$6771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cytyc Surgical Products, LLC | 4 | $22,791 |
| Hologic Sales And Service, LLC | 11 | $14,935 |
| Coloplast | 42 | $14,422 |
| Intuitive Surgical | 28 | $3,627 |
| Boston Scientific | 23 | $2,289 |
| Medtronic | 9 | $925 |
| Caldera Medical, Inc | 5 | $789 |
| Biom'up France SAS | 1 | $168 |
| AbbVie | 4 | $129 |
| Renovia Inc | 1 | $114 |
| Astellas Pharma US Inc | 1 | $25 |
| Femselect Inc. | 1 | $25 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$3,915
- Da Vinci Surgical System$2,933
- INTERSTIM$541
- Solyx SIS System$350
- Desara$210
- HemoBlast Bellows$168
- Advantage System$147
- Leva Pelvic Floor Trainer$114
- RESTORELLE$113
How this compares
$60,251 in reported general payments places this provider in the 90th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 37 | $19,813 |
| Estradiol | 141 | $8,139 |
| PremarinEstrogens, Conjugated | 11 | $4,158 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $435 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $25 | $19,81337 claims |
| PfizerPremarin | $13 | $4,15811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Los Angeles
- Christopher TarnayLos Angeles$41K
- Anne AckermanLos Angeles$32K
- Darlene MorrisseyLos Angeles$10K
- Yoko BeanLos Angeles$9K
- Victoria ScottLos Angeles$5K
- Thinh DuongLos Angeles$5K
- Victor VelascoLos Angeles$5K
- Andrey PetrikovetsLos Angeles$5K
- Atieh NovinLos Angeles$5K
- Michele TorosisLos Angeles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.